Travere Therapeutics, Inc.TVTXNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank77
3Y CAGR+28.7%
5Y CAGR-9.2%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+28.7%/yr
Quarterly compound
5Y CAGR
-9.2%/yr
Recent acceleration
Percentile
P77
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 11.52% |
| Q3 2025 | 5.12% |
| Q2 2025 | 5.27% |
| Q1 2025 | -24.45% |
| Q4 2024 | 20.10% |
| Q3 2024 | -4.88% |
| Q2 2024 | -52.60% |
| Q1 2024 | 95.11% |
| Q4 2023 | -3.04% |
| Q3 2023 | -8.88% |
| Q2 2023 | 10.98% |
| Q1 2023 | -0.53% |
| Q4 2022 | 5.40% |
| Q3 2022 | -4.25% |
| Q2 2022 | 5.42% |
| Q1 2022 | -8.94% |
| Q4 2021 | 28.43% |
| Q3 2021 | -6.56% |
| Q2 2021 | 8.05% |
| Q1 2021 | 24.90% |
| Q4 2020 | 18.66% |
| Q3 2020 | 5.06% |
| Q2 2020 | 1.79% |
| Q1 2020 | -16.15% |
| Q4 2019 | 8.59% |
| Q3 2019 | -12.43% |
| Q2 2019 | 13.43% |
| Q1 2019 | 4.53% |
| Q4 2018 | -1.40% |
| Q3 2018 | -5.84% |
| Q2 2018 | 39.88% |
| Q1 2018 | 25.85% |
| Q4 2017 | -0.17% |
| Q3 2017 | 0.66% |
| Q2 2017 | -6.61% |
| Q1 2017 | 3.89% |
| Q4 2016 | 8.95% |
| Q3 2016 | 4.26% |
| Q2 2016 | 20.47% |
| Q1 2016 | -5.05% |